@drjonschoeff's TRT claims need a closer look

What did @drjonschoeff actually say?

Dr. Jonathan Schoeff, a self-described board-certified surgeon and longevity medicine expert, made three core arguments: peptides used in biohacking circles lack high-quality human trial data, influencers promoting peptide stacks are selling rather than educating, and the absence of dramatic side effects has made it nearly impossible for users to know whether these compounds are doing anything at all. He also raised the possibility that some products sold as peptides may be little more than the sterile water used to reconstitute them. He did not name specific peptides, doses, or products, which is worth noting. His framing was cautionary throughout, not promotional.

This is a relatively rare thing on TikTok: a clinician using his platform to pump the brakes on a trend rather than accelerate it. That alone earns some scrutiny, because contrarian takes can be their own kind of content play.

Does the science back this up?

On the evidence question, Schoeff is largely correct, and the data is pretty thin. The peptide market has outpaced the research by years. Most compounds circulating in wellness communities, including BPC-157, TB-500, and various secretagogues, have animal or in-vitro data but minimal robust human randomized controlled trial support.

A 2022 review published in Frontiers in Pharmacology (Bitto et al.) examined growth hormone secretagogues and noted that while mechanistic plausibility exists, long-term safety and efficacy data in healthy adult populations remain insufficient. BPC-157, one of the most widely discussed peptides online, has been studied almost exclusively in rodent models. A 2019 review in Current Pharmaceutical Design (Seiwerth et al.) acknowledged promising animal findings but explicitly stated that human clinical evidence is lacking. Schoeff's characterization of this gap as a serious concern is accurate. Where he slightly overstates the case is in implying that zero human data exists. Peptides like CJC-1295 and ipamorelin have been studied in small human trials, though none approach the scale needed to establish long-term safety profiles.

What did they get wrong (or right)?

Schoeff gets the big picture right but stumbles on nuance in one notable area. His claim that peptides are "only slightly more impactful than the very sterile water" used to reconstitute them is too sweeping. That framing applies to unverified or mislabeled products, but it conflates product quality problems with pharmacological inactivity. Some peptides have demonstrated measurable biological activity in human studies. Tesamorelin, for instance, is FDA-approved for HIV-associated lipodystrophy, with published phase III trial data. Lumping a legitimate pharmaceutical peptide in with grey-market research chemicals does not serve accuracy.

His point about influencer affiliate codes functioning as a conflict-of-interest signal is well-taken and genuinely useful consumer advice. The affiliate model in health content is a real and underreported problem. His suggestion to get baseline labs before starting any peptide regimen is sound clinical reasoning, even if it sidesteps the question of which labs would actually be interpretable for most peptide protocols.

What should you actually know?

The regulatory situation matters here and Schoeff did not address it. Many peptides sold through compounding pharmacies or direct-to-consumer platforms exist in a legal grey zone. The FDA has removed several peptides, including BPC-157 and TB-500, from the list of approved bulk substances for compounding under 503A and 503B regulations. This means compounded versions of these specific compounds may not be legally dispensed by licensed pharmacies in the United States, depending on current enforcement status.

That is a concrete risk that goes beyond the evidence question. If you cannot verify that a peptide product has been manufactured under Current Good Manufacturing Practice standards and tested for identity and potency, you genuinely do not know what you are injecting. A 2023 analysis by the Alliance for Pharmacy Compounding noted that quality standards vary significantly across compounding facilities. Schoeff gestures at this with his sterile water comparison, but the actual regulatory and manufacturing picture is more specific and more actionable than he made it sound.

• Peptides differ enormously in their evidence base. Do not treat them as a single category.
• FDA approval status and compounding legality are separate questions worth researching for any specific compound.
• Lab monitoring is reasonable advice, but understand that standard hormone panels will not capture the activity of most research peptides.
• Influencer affiliate links are a real conflict of interest, not just a rhetorical point.